Advanced Aesthetic Technologies, Inc., a leader in aesthetic gel implant technology, announced that Algeness® VL (2.5% agarose gel) demonstrated equivalent efficacy, safety, and usability compared to those of NASHA-L based on a split-face study published in the Journal of Cosmetic Dermatology.

‘Agarose gel filler is a naturally occurring polymer gel with a three-dimensional structure similar to the extracellular matrix, which achieves its duration without the need for crosslinking. Our objective with this study of 66 patients was to determine the efficacy and safety of 2.5% agarose gel filler for the correction of nasolabial folds as compared with NASHA-L. Our assessments included assessment of the nasolabial fold (NLF), Wrinkle Severity Rating Scale (WSRS), Global Aesthetic Improvement Scale (GAIS [blinded investigator]), as well as subject satisfaction, adverse events, and usability,’ according to lead investigator Nicolò Scuderi, MD, of the Department of General and Plastic Surgery at the University of La Sapienza, Rome, Italy.

Among the 66 participants in the study, 46 individuals or 66.7% were available for evaluation at 3 months, when mean change in WSRS was identical for both products (−1.1 ± 0.4 for 2.5% agarose; −1.1 ± 0.4 for NASHA-L). Scores for each product remained similar across all time points and began to return to baseline between 7 and 8 months. GAIS score followed a similar pattern, rising between months 7 and 8 (2.7 ± 0.6 for 2.5% agarose at month 7 and 3.3 ± 0.5 at month 8, vs. 2.7 ± 0.6 for NASHA-L at month 7-3.3 ± 0.5 at month 8). All adverse events were transient in nature and resolved within 15 days, most events were mild in nature, and the number and severity of events was similar between the two fillers. According to Dr. Scuderi, ‘We continue to be impressed with the clinical outcomes of the novel Algeness® range of dermal fillers. This is the first 100% natural, biocompatible and biodegradable filler on the market to date, which differentiates it from other injectable products.’